Skip to main content Accessibility help
×
Home

Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis

  • Manuel J. Cuesta (a1), Elena García de Jalón (a1), M. Soledad Campos (a1) and Victor Peralta (a1)

Abstract

Background

Cognitive impairment in schizophrenia-spectrum disorders is highly prevalent and notably influences functional outcomes.

Aims

To characterise the cognitive effectiveness of second-generation antipsychotic drugs.

Method

One hundred consecutive and previously unmedicated patients with first-episode schizophrenia-spectrum disorders were admitted. Seventy-seven completed baseline, 1-month and 6-month psychopathological and neuropsychological assessments. Patients were randomised to risperidone or olanzapine treatment. Four final treatment allocation groups were defined since patients continued treatment in their normal setting: risperidone, olanzapine, mixed and no-antipsychotic groups.

Results

There were no differences in cognitive effectiveness between the four treatment groups. Reliable change index methods demonstrated that nearly a half of patients showed an improvement in Global Cognitive Score at the 6-month assessment. Improvement on the neuropsychological tests ranged from 17 to 54%.

A strong predictor of cognitive response was poor performance on baseline neuropsychological tests; response was moderately influenced by a low premorbid scholastic performance and IQ.

Conclusions

Cognitive improvement related to second-generation antipsychotic drugs appeared within the first 4 weeks of treatment and persisted at 6 months irrespective of treatment group. Greater cognitive dysfunction at baseline and lower premorbid cognitive background predicted cognitive improvement in our sample.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis
      Available formats
      ×

Copyright

Corresponding author

Dr Manuel J. Cuesta, Psychiatric Unit, Virgen del Camino Hospital c/ Irunlarrea 4, E-31008 Pamplona, Spain. Email: mcuestaz@cfnavarra.es

Footnotes

Hide All

The Navarrás Government provided funding for implementation of the study (grants 946/2005 and 55/2007).

Declaration of interest

None.

Footnotes

References

Hide All
1 Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426–45.
2 Saykin, AJ, Gur, RC, Gur, RE, Mozley, PD, Mozley, LH, Resnick, SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48: 618–24.
3 Cuesta, MJ, Peralta, V, Caro, F, de Leon, J. Schizophrenic syndrome and Wisconsin Card Sorting Test dimensions. Psychiatry Res 1995; 58: 4551.
4 Heaton, RK, Gladsjo, JA, Palmer, BW, Kuck, J, Marcotte, TD, Jeste, DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001; 58: 2432.
5 Kraus, MS, Keefe, RSE. Cognition as an outcome measure in schizophrenia. Br J Psychiatry 2007; 191 (suppl 50): s4651.
6 Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–30.
7 Green, MF. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 2007; 164: 992–4.
8 Cuesta, MJ, Peralta, V, Zarzuela, A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res 1998; 33: 141–50.
9 Heaton, RK, Crowley, TJ. Effects of psychiatry disorders and their somatic treatments on neuropsychological test results. In Handbook of Clinical Neuropsychology (eds Filskov, SB, Boll, TJ): 481525. Wiley, 1981.
10 Medalia, A, Gold, J, Merriam, A. The effect of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 1988; 3: 249–71.
11 Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive fuctions in schizophrenia. J Abnorm Psychol 1989; 98: 367–80.
12 Cassens, G, Inglis, AK, Appelbaum, PS, Gutheil, TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477–99.
13 King, DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157: 799811.
14 Weickert, TW, Goldberg, TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 2005; 7: 304–10.
15 Mishara, AL, Goldberg, TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013–22.
16 Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007; 89: 211–24.
17 Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633–47.
18 Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 1999; 174 (suppl 38): s4451.
19 Goldberg, TE, Goldman, RS, Burdick, KE, Malhotra, AK, Lencz, T, Patel, RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115–22.
20 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR). APA, 2000.
21 Andreasen, NC, Flaum, M, Arndt, S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615–23.
22 Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663–67.
23 Osterberg, L, Blaschke, T. Adherence to medication. N Engl J Med 2005; 353: 487–97.
24 Reitan, RM, Wolfson, D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychology Press, 1985.
25 Wechsler, DA. Standarized memory scale for clinical use. J Psychology 1945; 19: 8795.
26 Spaulding, W, Garbin, CP, Dras, SR. Cognitive abnormalities in schizophrenic patients and schizotypal college students. J Nerv Ment Dis 1989; 177: 717–28.
27 Penn, DL, Van Der Does, W, Spaulding, W, Garbin, CP, Linszen, D, et al. Information processing and social cognitive problem solving in schizophrenia. J Nerv Ment Dis 1993; 181: 1320.
28 Hair, JF, Black, B, Babin, B, Anderson, RE, Tatham, RL. Multivariate Data Analysis (6th edn). Pearson Prentice Hall, 2005.
29 Brown, L, Sherbenou, RJ, Johnsen, SK. TONI-2 Test de Inteligencia No Verbal. TEA Ediciones, 1995.
30 Jacobson, NS, Truax, P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12–9.
31 Saykin, AJ, Shtasel, DL, Gur, RE, Kester, DB, Mozley, LH, Stafiniak, P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51: 124–31.
32 Bilder, RM, Goldman, RS, Robinson, D, Reiter, G, Bell, L, Bates, JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157: 549–59.
33 Lee, SM, Chou, YH, Li, MH, Wan, FJ, Yen, MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1101–7.
34 Townsend, LA, Norman, RM. Course of cognitive functioning in first episode schizophrenia spectrum disorders. Expert Rev Neurother 2004; 4: 61–8.
35 Mohamed, S, Paulsen, JS, O'Leary, D, Arndt, S, Andreasen, N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999; 56: 749–54.
36 Riley, EM, McGovern, D, Mockler, D, Doku, VC, OCeallaigh, S, Fannon, DG, et al. Neuropsychological functioning in first-episode psychosis – evidence of specific deficits. Schizophr Res 2000; 43: 4755.
37 Goldstein, G, Shemansky, WJ. Influences on cognitive heterogeneity in schizophrenia. Schizophr Res 1995; 18: 5969.
38 González-Blanch, C, Alvarez-Jiménez, M, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, Vázquez-Barquero, JL, Crespo-Facorro, B. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry Clin Neurosci 2006; 256: 364–71.
39 Peralta, V, Cuesta, MJ. A dimensional and categorical architecture for the classification of psychotic disorders. World Psychiatry 2007; 6: 36–7.
40 Reichenberg, A, Weiser, M, Rapp, MA, Rabinowitz, J, Caspi, A, Schmeidler, J, et al. Pre-morbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res 2006; 85: 4957.
41 Cannon, M, Caspi, A, Moffit, TE, Harrington, H, Taylor, A, Murray, RM, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002; 59: 449–56.
42 Heaton, RK, Temkin, N, Dikmen, S, Avitable, N, Taylor, MJ, Marcotte, TD, et al. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol 2001; 16: 7591.
43 Keefe, RS, Sweeney, JA, Gu, H, Hamer, RM, Perkins, DO, McEvoy, JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1061–71.
44 Cuesta, MJ, Peralta, V, Zarzuela, A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001; 48: 1728.
45 Lezak, MD. Neuropsychological Assessment (3rd edn). Oxford University Press, 1995.
46 Vickers, AJ. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BMC Med Res Methodol 2003; 3: 22.
47 Allison, DB, Allison, RL, Faith, MS, Paultre, F, Pi-Sunyer, FX. Power and money: designing statistically powerful studies while minimizing financial costs. Psychol Methods 1997; 2: 2033.

Related content

Powered by UNSILO
Type Description Title
PDF
Supplementary materials

Cuesta et al. supplementary material
Supplementary Material

 PDF (138 KB)
138 KB

Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis

  • Manuel J. Cuesta (a1), Elena García de Jalón (a1), M. Soledad Campos (a1) and Victor Peralta (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis

  • Manuel J. Cuesta (a1), Elena García de Jalón (a1), M. Soledad Campos (a1) and Victor Peralta (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *